Teplizumab became the first FDA-approved drug for the delay and prevention of type 1 diabetes, but it also comes with its own challenges. Presenters, including Kevan C. Herold, MD, shared the benefits of teplizumab along with some of the barriers faced for the research community, clinical practice, and patients.
Get email updates from ADAMeetingNews.org
Subscribe to get regular news updates about the Scientific Sessions.
You can also subscribe to receive other email communications from the American Diabetes Association.